Neuroticism is a relatively stable personality trait characterized by negative emotionality (for example, worry and guilt) 1 ; heritability estimated from twin studies ranges from 30 to 50% 2 , and SNP-based heritability ranges from 6 to 15% [3] [4] [5] [6] . Increased neuroticism is associated with poorer mental and physical health 7, 8 , translating to high economic burden 9 . Genome-wide association studies (GWAS) of neuroticism have identified up to 11 associated genetic loci 3, 4 . Here we report 116 significant independent loci from a GWAS of neuroticism in 329,821 UK Biobank participants; 15 of these loci replicated at P < 0.00045 in an unrelated cohort (N = 122,867). Genetic signals were enriched in neuronal genesis and differentiation pathways, and substantial genetic correlations were found between neuroticism and depressive symptoms (r g = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07) and subjective well-being (r g = -0.68, s.e. = 0.03) alongside other mental health traits. These discoveries significantly advance understanding of neuroticism and its association with MDD.
.

Genome-wide association studies (GWAS) of neuroticism have identified up to 11 associated genetic loci
. Here we report 116 significant independent loci from a GWAS of neuroticism in 329,821 UK Biobank participants; 15 of these loci replicated at P < 0.00045 in an unrelated cohort (N = 122,867). Genetic signals were enriched in neuronal genesis and differentiation pathways, and substantial genetic correlations were found between neuroticism and depressive symptoms (r g = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07) and subjective well-being (r g = -0.68, s.e. = 0.03) alongside other mental health traits. These discoveries significantly advance understanding of neuroticism and its association with MDD.
Understanding why people differ in neuroticism will provide an important contribution to understanding people's susceptibility to poor mental health throughout the life course. The strong genetic correlation between neuroticism and mental health, especially anxiety and MDD 10, 11 , means that exploring the genetic contribution to differences in neuroticism is one way to understand more about these common and burdensome, but etiologically intractable, illnesses. In the largest GWAS of MDD (130,664 cases versus 330,470 controls), 44 independent associated genetic loci were identified 12 . UK Biobank has health, medical and genetic information for over 500,000 individuals aged 39-73 years from the UK, assessed between 2006 and 2010 13, 14 . We performed a genome-wide association analysis of trait neuroticism in 329,821 unrelated self-described white British adults (152,710 male (46.3%)) with high-quality genotype data (Methods). Neuroticism was measured by total score on the 12-item Eysenck Personality Questionnaire-Revised Short Form (EPQ-R-S) 15 ; missing item data (ranging from 1.8 to 4.7%) were imputed with reference to age and sex, and individuals with more than four missing items were excluded ( Supplementary Fig. 1 , Supplementary Table 1 and Supplementary Note). For analysis, the score was residualized for the effects of age, sex, assessment center, genotype batch, array and 40 genetic principal components. This score was tested against 18,485,882 biallelic SNP variants, based on the Haplotype Reference Consortium (HRC) panel 16 , with a minor allele frequency (MAF) ≥ 0.0005 and an information/imputation quality score of ≥ 0.1 under an additive model. The distribution of obtained versus expected results under the null hypothesis showed some genomic inflation, with a lambda of 1.15 (quantile-quantile plot shown in Supplementary Fig. 2 ). Univariate linkage disequilibrium score (LDSC) regression 17 estimates indicated that 96.8% of this inflation was due to the presence of a large polygenic signal, with the intercept being close to 1 (1.02, s.e. = 0.01). The SNP-based heritability of neuroticism was estimated at 0.108 (s.e. = 0.005) using LDSC.
Genome-wide significance (P < 5 × 10 −8 ) was demonstrated for 10,353 genetic variants, with a further 17,668 variants at a suggestive level (P < 1 × 10 Table 2 ). The Manhattan plot is shown in Fig. 1 , and gene annotation for the significant SNPs is presented in Supplementary Table 3 . SNPs identified in previous neuroticism GWAS were mostly significant in our sample (Supplementary Table 2 and Supplementary Note), and substantial overlap with MDD SNPs (75%) and genes was found (Supplementary Table 4 and Supplementary Note). The major histocompatibility complex (MHC) region has previously been linked to schizophrenia, a psychiatric comorbidity trait (including MDD) 18, 19 and MDD 12 . This region contained three significant independent genetic loci associated with neuroticism; two were in genes connected with schizophrenia (GABBR1 and TNXB) 20, 21 . The primary associated SNP for schizophrenia 18 , rs2021722, was present in our study and was nominally significant (P = 9.42 × 10 −5 ). The previous MHC associations in relation to our findings are shown in Supplementary Fig. 3 .
Of the significant SNPs, 116 were independent (r 2 > 0.1 and within 500 kb of the significant index SNP); these lead SNPs are shown in Supplementary 
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SNPs, region size and genes within the linkage disequilibrium (LD) interval. Seventy-three lead SNPs were located within genes: 5 were exonic (in MSRA, NOS1, PINX1, ZCCHC14 and C12orf49) and a further 2 were coding SNPs in RPP21 (missense) and AGBL1 (synonymous), 55 were intronic and 10 were noncoding RNA variants; 42 were intergenic. For the 116 independent SNPs, evidence of expression quantitative trait loci (eQTLs) was explored using the Genotype-Tissue Expression (GTEx) database, with 44 found to be eQTLs (Supplementary Table 5 ). A RegulomeDB score was used to identify SNPs with likely regulatory function. Thirty-three of the 116 SNPs were included in the RegulomeDB database, and eight of these had a score < 3, indicating that they are likely to be involved in gene regulation (Supplementary Table 5 ).
Replication of the significant association signals in UK Biobank was sought from the results of a GWAS meta-analysis of neuroticism that we performed using data from 23andMe (N = 59,206) 22 and the Genetics of Personality Consortium (GPC-2; N = 63,661) 23 . Of the 10,353 genome-wide significant SNPs in UK Biobank, 10,171 were available in the replication cohorts, and the association for 8,774 of these increased in significance when the replication cohorts were subjected to meta-analysis with UK Biobank. This indicates a consistent direction of allelic effect (Supplementary Table 6 ).
Of the 116 independent associated SNPs, 111 were present in the replication cohort, with 51 nominally significant (P < 0.05; Supplementary Table 5 ) and 15 significant at a Bonferroni-corrected level (P < 0.00045; Table 1 ). One of these, rs2953805, was previously associated with morning chronotype 24 , a trait relating to lower neuroticism 25 , and showed allelic effects in the expected direction. The low replication rate (13.5%) at a strict corrected significance level reflects the finding that effect sizes are extremely small (up to a 0.02 s.d. increase in neuroticism score per allele), and similarly large replication samples will thus be required to confirm effects. Regional association plots for chromosomes 8, 11 and 22, in which multiple genes were present in the associated LD region, are shown in Fig. 2a-c . Of the five chromosome 8 loci, only one lead SNP tagged a well-known inversion, previously linked to neuroticism ( Supplementary Fig. 4 and Supplementary Note), although associations in the broad region have been attributed to the inversion 4 and so this region might cautiously be considered as a single locus.
All 69 genes located within the 15 replicated loci were classified in terms of their molecular function, biological process and protein class using the Protein Analysis Through Evolutionary Relationships (PANTHER) classification system, which includes 14,710 protein families categorized into 76,032 functionally distinct subfamilies 26 . A large number of the genes within the replicated loci (i) encode nucleic acid-binding and transcription factors, (ii) contribute to metabolic and cellular processes and (iii) have a role in binding and catalytic activity molecular functioning. Transcription factors, in particular, have been implicated in the etiology of depression 27, 28 , and microRNAs-which have been linked with anxiety 29 and depression 30 -might target genes with roles in binding (for example, POLR3H). The PsyGeNET (v2.0) database showed that, of the 69 genes, 4 have been associated with psychiatric disorder (Supplementary Table 7 ): DRD2 (bipolar disorder, depression, substance use/dependence, delirium), EP300 (alcoholic intoxication), TEF (depression) and MSRA (schizophrenia). Variants in CACNA1E have been associated with cross-psychiatric disorder overlap and migraine 18, 31 . A GTEx database search for the 15 replicated SNPs showed that 9 were associated with significant regulation of 60 genes expressed in a variety of tissues (Supplementary Table 8 ). Of the 30 brain expression associations, half were in the cerebellum, with 4 SNPs regulating 10 genes. Notably, magnetic resonance imaging (MRI) studies have shown associations between cerebellar volume and neuroticism as well as cerebellar blood flow in response to negative emotional cues 32, 33 . In a BRAINEAC search, all SNPs were identified as eQTLs in at least one brain region at a nominal significance level (P < 0.05) and ten were supported at a Bonferroni-corrected significance level of P < 0.0003 (Supplementary Table 9 ). Of potential interest, rs7107356, a newly associated SNP in an intergenic region of chromosome 11, regulates MTCH2 in the cerebellar cortex (P = 4.5 × 10
−6
). MTCH2 is involved in metabolic pathways and cell function 34 , and variants of this gene have been associated with body mass index (BMI) 35 .
Gene-based analysis of the GWAS results was performed using MAGMA 36 ; 249 genes were significantly associated at a Bonferronicorrected significance level (α = 0.05/18,080; P < 2.77 × 10 −6 ; Supplementary Table 10 ). Three of these (STH, HIST1H3J and HIST1H4L) were genes containing a single SNP. Of the replicated independent genome-wide associated SNPs that were within genes, the following significant genes were corroborated in the genebased results: CACNA1E, XKR6, MSRA, LINGO2, CELF4, ZC3H7B Letters Nature GeNetics and BAIAP2. SNP rs6981523, previously identified in 23andMe for neuroticism 22 , was an intergenic SNP near XKR6; this gene was the second most significant gene in our gene-based analysis (P = 6.55 × 10 −32 ): neuron spine (cellular), homophilic cell adhesion via plasma membrane adhesion molecules (biological), neuron differentiation (biological), cell-cell adhesion via plasma membrane adhesion molecules (biological) and neurogenesis (biological). See Table 2 for further details. Of note is the neurogenesis pathway, which is hypothetically implicated in depression (and, to a lesser extent, anxiety) on the basis of stress reducing neurogenesis in the hippocampus and the action of antidepressants on brain circuitry 37, 38 . Further, variants in PLXNA2, potentially involved in adult neurogenesis, have been associated with anxiety and neuroticism 39 . Cell adhesion molecules have been implicated in neuropsychiatric disorder 40 and protocadherins in particular have been associated with neuroticism and risk of mood disorder 41 , supporting the importance of cell adhesion pathways. A further gene set analysis of genes encoding proteins that can bind to antidepressant drug molecules was significant (P = 0.005), reaffirming the dependency of neuroticism and depression on shared biological pathways. This is consistent, for example, with findings for CRHR1 (highlighted in our SNP-and gene-based analyses), a gene involved in normal hormonal responses to stress (with the glucocorticoid pathway being a relevant and well-known target) and associated with anxiety, depression and neuroticism 3, 42, 43 . The finding that genes influencing neuroticism identify pathways involved in the action of currently prescribed and effective antidepressants suggests that neuroticism could be a potentially useful clinical stratifying factor for effective antidepressant action. There may also be clinical utility in knowing a person's level of neuroticism after the occurrence of a stressful life event and preempting onset of depression via drug therapy in those with high levels of neuroticism. Because our GWAS of neuroticism identifies signals associated with the known biological action of existing antidepressants, it may be useful as a means of discovering new (or repurposing) pharmacological interventions for MDD.
LD score regression 44 was used to estimate the genetic correlation between neuroticism and a variety of health traits (Supplementary  Tables 11 and 12 ). The strongest correlation was observed for depressive symptoms (r g = 0.82, s.e = 0.03). MDD, subjective wellbeing and tiredness showed moderate to strong absolute correlations (0.62-0.69). The stronger correlation for depressive symptoms than for depressive disorder might be indicative of improved sensitivity for continuous versus dichotomous traits but might also point to inventory item overlap (greater conceptual similarity) for depressive symptoms and/or noise in MDD diagnosis. Genetic correlations with neuroticism were moderate for self-rated health (0.41), moderate to low for schizophrenia, attention deficit hyperactivity disorder (ADHD), anorexia nervosa and educational attainment (~|0.20|), and low for bipolar disorder and smoking status (|0.11|). The genetic correlation of 1 between Eysenck neuroticism and other neuroticism scales (used by 23andMe and the GPC-2) confirms that GWAS meta-analysis based on different measurement instruments is valid. Mendelian randomization was used to determine whether the genetic correlation between neuroticism and the non-psychiatric variables (less likely to be influenced by pleiotropy) of smoking status and educational attainment represented a causal relationship from neuroticism. For smoking status, the β of 0.23 was significant in the inverse-variance-weighted model (P = 0.00002), which is preferred in the presence of heterogeneity (P = 0.001); the MR Egger regression did not show significant directional pleiotropy (intercept = 0.02, P = 0.10), thus supporting a causal relationship. For educational attainment, the β of -0.09 was significant (P = 8.35 × 10
) in the inverse-variance-weighted model (heterogeneity P = 5.87 × 10 −7 ), with no evidence of directional pleiotropy (intercept = 0, P = 0.23). Although theoretically less plausible, the reverse causal direction should be investigated in UK Biobank once a large number of significant SNPs influencing smoking status and educational attainment have been found in nonoverlapping samples.
Polygenic profile analyses based on the SNP inclusion threshold with the optimal signal-to-noise ratio (P < 0.05) indicated that the neuroticism polygenic score explained 2.79% of the variance in neuroticism (β = 0.19, P = 2.65 × 10
−47
) and 0.8% of the variance in depression status (odds ratio (OR) = 1.25, P = 1.53 × 10 −8 ) in Generation Scotland (N = 7,388) 45 . Results for polygenic scores in Generation Scotland based on other SNP significance inclusion thresholds (0.01, 0.05, 0.1, 0.5 and 1) from the UK Biobank GWAS can be found in Supplementary Table 13 .
The combination in UK Biobank of a large sample with homogenous ancestry and a well-validated neuroticism scale has afforded the discovery of 15 stringently replicated genetic loci that influence Letters Nature GeNetics neuroticism levels, 4 of which are new. Most lead variants were associated with gene regulation, with half of these genes expressed in the brain; single-variant and gene associations overlapped substantially with MDD findings, and genes in antidepressant-targeted pathways were over-represented. There was also support for neuroticism having causal effects on socioeconomic markers. These discoveries promise paths to understanding the mechanisms whereby some people become depressed and broader human differences in happiness, and they are a resource for those seeking novel drug targets for major depression. After millennia in which scholars and researchers have sought the sources of individual differences in proneness to dysphoria 46 , the present study adds to explanations of the (genetic) anatomy of melancholy.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0013-8. The number of independent signals from the GWAS analysis was determined using LD clumping in PLINK v1.90b3i 47 (see URLs). The LD structure was based on SNPs with P < 1 × 10 −3 that were extracted from the imputed genotypes. Index SNPs were identified (P < 5 × 10 −8
Letters
Nature GeNetics
), and clumps were formed for SNPs with P < 1 × 10 −5 that were in LD (r 2 > 0.1) and within 500 kb of the index SNP. SNPs were assigned to no more than one clump.
Meta-analysis of GWAS results.
Two meta-analyses were performed. First, to check for replication of the significant (P < 5 × 10
) GWAS signals in UK Biobank, results from a meta-analysis of 23andMe 22 (full GWAS summary statistics were made available from 23andMe) and GPC-2 23 (full GWAS summary statistics were publicly available; see URLs) were used. This meta-analysis was conducted using METAL 48 ; because of the lack of phenotype harmonization across the cohorts, a sample-size-weighted meta-analysis was preferred. A second meta-analysis of UK Biobank and the replication cohorts was performed using the same method but only for the SNPs that were significant in UK Biobank.
Genome-wide gene-based analysis.
Gene-based analysis of neuroticism was performed using MAGMA 36 , which provides gene-based statistics derived using the results of the GWAS. Genetic variants were assigned to genes on the basis of their position according to NCBI Build 37.3, with no additional boundary placed around the genes. This resulted in a total of 18,080 genes being analyzed. The European panel of the 1000 Genomes Project data (phase 1, release 3) was used as a reference panel to account for LD. A genome-wide significance threshold for genebased associations was calculated using the Bonferroni method (α = 0.05/18,080; P < 2.77 × 10
−6
).
Functional annotation and gene expression.
For the 116 independent genomewide significant SNPs identified by LD clumping, evidence of eQTLs and functional annotation were explored using publicly available online resources. The GTEx Portal (see URLs) was used to identify eQTLs associated with the SNPs. Functional annotation was investigated using the RegulomeDB database 49 (see URLs). In addition to GTEx searches, we investigated whether any of the 15 replicated SNPs were brain eQTLs by entering them into the brain eQTL database BRAINEAC (see URLs), which contains gene expression data across ten brain regions (cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, temporal cortex, thalamus and intralobular white matter). Genes located in the same region as the replicated independent loci were investigated for protein function using the PANTHER database (see URLs), which stores data on the evolution and function of protein-coding genes from the sequenced genomes of diverse species 50 ; our focus here was on Homo sapiens. Uncharacterized gene function is predicted via phylogenetic branching information, and the resource enables biological pathway annotation.
Pathway analysis. Biological pathway analysis was performed on the gene-based analysis results. This gene set enrichment analysis was conducted using gene annotation files from the Gene Ontology (GO) Consortium (see URLs) 51 taken from the Molecular Signatures Database (MSigDB) v5.2. The GO Consortium includes gene sets for three ontologies: molecular function, cellular components and biological function. The annotation file consisted of 5,917 gene sets that were corrected for multiple testing using the MAGMA default setting correcting for 10,000 permutations.
To determine whether the genetic targets of antidepressants were enriched for neuroticism, we performed a competitive gene set analysis using MAGMA. Gene sets corresponding to Anatomical Therapeutic Chemical Classification System code N06A Antidepressants (within the Psychoanaleptics class) were downloaded (see URLs). This resulted in a set of 110 unique genes corresponding to genes that are the targets of antidepressants. Enrichment for neuroticism was tested against a set of 5,483 'druggable' autosomal genes (see URLs), that is, genes encoding proteins that can bind to drug-like molecules. Of the 110 genes encoding antidepressant targets, 86 were found among the 5,483 druggable genes.
Linkage disequilibrium score regression. Univariate LDSC regression 17 was used to test for residual stratification in our GWAS summary statistics and to derive a heritability estimate. LD regression was performed by regressing GWAS test statistics (χ 2 ) onto each SNP's LD score (the sum of the squared correlations between the minor allele count of a SNP and the minor allele count of every other SNP). This regression allows for estimation of heritability from the slope and provides a means to detect residual confounders through the intercept. The percentage of inflation in the test statistic due to polygenic signal can be derived by subtracting the LDSC ratio ((intercept -1)/(mean χ 2 -1)), which represents inflation due to population stratification and other confounding, from 1 and multiplying by 100. Bivariate LDSC regression 44 was used to derive genetic correlations between neuroticism and 18 psychiatric and physical health phenotypes (Supplementary Table 11 ). For Alzheimer's disease, a 500-kb region surrounding APOE was excluded and the analysis was rerun (Alzheimer's disease (500 kb)). The genetic correlation between neuroticism as measured by different inventories was also estimated. Further details, including the sources of GWAS summary statistics, can be found in the Supplementary Note. Sample overlap could not be controlled for in the LDSC analyses because the exact overlap between the UK Biobank data and the health traits data was unknown. In such a case, constraining the intercept to a 'wrong' value could lead to biased estimates. Any sample overlap in the present analyses would only affect the intercept of the regression and could lead to inflated standard errors, but would not affect the genetic correlation 12 .
Mendelian randomization. Two-sample Mendelian randomization (MR) was performed using the TwoSampleMR 52 package implemented in R. GWAS summary statistics from a GWAS of smoking status in 74,053 Europeans 53 were used to create outcome data for the MR between neuroticism and smoking status. Seventy-seven independent SNPs associated with neuroticism were available in the smoking status GWAS summary data to test for a causal effect of neuroticism on smoking status. There were no significant SNP signals for smoking status to test the reverse causation model. GWAS summary statistics from a GWAS of educational attainment in 126,559 individuals of European ancestry 54 were used to create outcome data for the MR between neuroticism and educational attainment. Seventy-five independent SNPs associated with neuroticism were available in the educational attainment GWAS summary data to test for a causal effect of neuroticism in educational attainment. There were too few significant SNPs available for educational attainment to test for a causal effect of educational attainment on neuroticism. Sensitivity analyses were performed to test for heterogeneity, and a further test for horizontal pleiotropy was carried out.
Polygenic prediction into Generation Scotland. Polygenic profile analyses were performed to predict neuroticism and depression status in Generation Scotland 45 . Polygenic profiles were created in PRSice 55 using the UK Biobank neuroticism SNP-based association results for 7,388 unrelated individuals in Generation Scotland. SNPs with MAF < 0.01 were removed before creating the polygenic profiles. Clumping was used to obtain SNPs in LD with r 2 < 0.25 within a 250-kb window. Individuals were removed from Generation Scotland if they had contributed to both UK Biobank and Generation Scotland (N = 302). Polygenic profile scores were created based on the significance of each association in UK Biobank with the neuroticism phenotype, at P-value thresholds of 0.01, 0.05, 0.1, 0.5 and 1 (all SNPs). Linear regression models were used to examine associations between the polygenic profile and neuroticism score in Generation Scotland, adjusting for age at measurement, sex and the first ten genetic principal components to account for population stratification. Logistic regression models were used to examine depression status, adjusting for the same covariates as in the neuroticism models. The false discovery rate (FDR) method was used to correct for multiple testing across the polygenic profiles for neuroticism at all five significance thresholds 56 . We did not perform a sample size calculation because the resource was providing the largest single sample to date with neuroticism and whole genome data.
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Data exclusions
Describe any data exclusions.
We excluded all non-Caucasian participants to guard against population stratification effects. This was decided prior to receiving the data. Any poor quality data (excessive missing phenotypes, poor genotyping imputation) were also excluded. Only genetically unrelated individuals were retained in the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
We replicated 15 of our significant (independent) SNP associations in an independent sample of 122,867 individuals.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Our study was not experimental, it was a population-based genetic association study, and therefore, randomization was not applicable.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
We did not have control and experimental groups in our study, so blinding is not applicable.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
